Analyst Bursts Edwards’ Bubble On PARTNER Percutaneous Valve Trial
This article was originally published in The Gray Sheet
Executive Summary
An analyst raised doubts last week about Edwards Lifesciences' ability to gain approval for all studied indications in its closely watched U.S. trial for the Sapien percutaneous aortic valve
You may also be interested in...
Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys
Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion
Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys
Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion
Edwards’ Sapien Sales Drive 24% Gain In Q2 Heart Valve Revenue
Edwards Lifesciences' heart valve sales soared 24% in the second quarter from a year ago, to $162.6 million, driven by European sales of its Sapien transcatheter heart valve, the company says